Sat.Jan 27, 2024 - Fri.Feb 02, 2024

article thumbnail

Pfizer's layoff campaign ramps back up with dozens of SF-area cuts expected next month

Fierce Pharma

The start of the new year doesn’t seem to have dulled the zeal of Pfizer’s global cost-cutting campaign, which has already left hundreds of jobs in its wake. | Come mid-February, Pfizer will lay off some 52 employees at a facility in South San Francisco, according to a recent Worker Adjustment and Retraining Notification Act alert. The site is the former headquarters of Global Blood Therapeutics.

336
336
article thumbnail

Merck is on the lookout for more opportunities within immunology

Pharmaceutical Technology

At the JP Morgan Healthcare conference, Merck (MSD) indicated its eagerness to continue to establish its place in the immunological space.

Insiders

Sign Up for our Newsletter

This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Trending Sources

article thumbnail

We’ve Actually Treated Tens of Thousands of People on Ozempic to Date – Here’s What Really Happens and What It Likely Means for Solving Our Obesity Epidemic

MedCity News

We and our collective organizations’ providers have treated 10,000’s of Americans, who suffer from obesity and/or Type 2 diabetes with GLP-1 drugs. And we believe we have important observations to share.

Biopharma 144
article thumbnail

Novartis calls time on Tim3 drug sabatolimab in MDS

pharmaphorum

Novartis ends development of Tim3 antibody sabatolimab in myelodysplastic syndromes after failed phase 3 trial.

134
134
article thumbnail

AI Strategies for Sales Managers: How to Cut Down on Tedious Admin Work

What if you could help your sellers stop wasting 72% of their day on non-selling activities and focus on bringing in revenue? Incorporating AI in your enablement workflows can help you cut down on busy work, get projects done faster, and let your team (and you!) focus on making a bigger impact. We put together this guide to show you how to use AI to cut time and costs for projects, including collateral creation, development of training videos, and automating tedious processes.

article thumbnail

Biogen abandons Aduhelm efforts, focuses on Eisai-partnered Leqembi and pipeline drugs

Fierce Pharma

More than two years after Aduhelm's controversial and ill-fated FDA accelerated approval, Bi | Biogen is discontinuing its first Alzheimer's disease therapy, Aduhelm, after walking a rocky path. The company is taking a $60 million charge, halting sales and terminating a confirmatory trial.

FDA 313
article thumbnail

Charting a course for ongoing omnichannel excellence

Dominic Tyer

Successful customer engagement will require pharma companies to maintain a rigid focus throughout the journey

Pharma 130

More Trending

article thumbnail

Study reveals SARS-CoV-2 can infect dopamine neurons causing senescence

PharmaTimes

Dopamine neuron senescence is a hallmark of Parkinson’s disease

Medicine 125
article thumbnail

FDA sets date for high-profile CAR-T adcomm for Bristol’s Abecma, J&J’s Carvykti

Fierce Pharma

Mark your calendars, oncology drug and CAR-T therapy developers. | Mark your calendars, oncology drug and CAR-T therapy developers. The FDA has decided on a date for a highly anticipated advisory committee meeting for Bristol Myers' Abecma and J&J's Carvykti.

FDA 306
article thumbnail

Novo Nordisk sales surge drives value towards $500bn

pharmaphorum

A surge in 2023 sales and profits fuelled by diabetes and obesity drugs has driven Novo Nordisk's valuation toward $500bn

Sales 121
article thumbnail

How Artificial Intelligence Could Be the Ultimate Weapon Against Cancer

MedCity News

Even just a year ago, we couldn’t fathom a cure for cancer. Now, we can. Artificial intelligence (AI) is rapidly transforming the healthcare industry, with its ability to process and analyze vast amounts of data. Cancer treatment is one area that could benefit significantly from AI, as it can aid in early detection, precise diagnosis, and personalized treatment plans.

article thumbnail

From Diagnosis to Delivery: How AI is Revolutionizing the Patient Experience

Speaker: Simran Kaur, Founder & CEO at Tattva Health Inc.

The healthcare landscape is being revolutionized by AI and cutting-edge digital technologies, reshaping how patients receive care and interact with providers. In this webinar led by Simran Kaur, we will explore how AI-driven solutions are enhancing patient communication, improving care quality, and empowering preventive and predictive medicine. You'll also learn how AI is streamlining healthcare processes, helping providers offer more efficient, personalized care and enabling faster, data-driven

article thumbnail

Cancer treatment could identify patients most likely to respond to cancer drugs

PharmaTimes

Tumours with high mtDNA mutations more likely to respond to Opdivo

Patients 120
article thumbnail

GSK confirms Arexvy is a blockbuster but says the RSV battle has just begun

Fierce Pharma

Beaten to the punch by Pfizer in developing a vaccine for COVID, GSK has regained some of its lost luster as a vaccine powerhouse with its advancement of respiratory syncytial virus (RSV) shot Arex | GSK's RSV vaccine Arexvy generated $1.5 billion in sales in 2023 compared to $890 million for Pfizer's Abrysvo. But the British pharma major says that the successful launch represents just one round of a boxing match, and much is still to be decided, especially with Moderna expected to joi

Sales 300
article thumbnail

Tonix closes in on the first new fibromyalgia drug in more than a decade

PharmaVoice

In addition to the chronic disease, the non-opioid drug may have applications in other painful conditions.

119
119
article thumbnail

Neuro Biotech Alto Adds $128M in IPO Cash for Biomarker-Based Psych Drugs

MedCity News

Alto Neuroscience will apply the IPO proceeds toward clinical tests of its psychiatric drugs in patients who exhibit certain biomarkers. The company’s two most advanced programs are depression drugs in mid-stage development.

Patients 124
article thumbnail

Optimizing Clinical Supply Strategy: Navigating Challenges & Finding Your Ideal Model

article thumbnail

International consortium identifies biomarkers for cardiovascular disease in diabetes

PharmaTimes

Type 2 diabetes is estimated to affect 462 million people worldwide

119
119
article thumbnail

Merck still in the market for deals in the $1B to $15B range, CEO says

Fierce Pharma

Even after the acquisitions of Prometheus and Acceleron, Merck is ready to make more deals in the $1 to $15 billion range, according to CEO Rob Davis.

Marketing 296
article thumbnail

The Path for Prescription Drug Sales

Pharmaceutical Commerce

A dive into this market reveals that the latest numbers yield promising results—a global value of a worldwide $1.6 trillion—but it will continue to be attributed to past, present, and future healthcare spending.

article thumbnail

Cigna MA Sale to HCSC Could Still Clear Way for Humana Acquisition, Expert Says

MedCity News

Despite Cigna and Humana ditching their pursuits to combine in December, one industry expert believes there’s still a chance after Cigna announced its plan to sell its Medicare Advantage business to Health Care Service Corp.

Sales 124
article thumbnail

How Machine Learning Drives Clinical Trial Efficiency

Clinical trial data management is increasingly challenging as studies grow in complexity. Quickly accessing and analyzing study data is vital for assessing trial progress and patient safety. In this paper, we explore real-time data access and analysis for proactive study management. We investigate using adverse event (AE) data to monitor safety and discuss a clinical analytics platform that supports collaboration and data review workflows.

article thumbnail

Digital health hit hard by VC slump in 2023, says report

pharmaphorum

Digital health investments has halved for the second year in a row, according to a new report from CB Insights

114
114
article thumbnail

WuXi Biologics plays defense after US bill brands certain Chinese biopharmas as security threats

Fierce Pharma

New legislation aimed at blocking a group of Chinese biopharma firms from tapping into U.S. federal funding has sent shares tumbling in recent days. | New legislation aimed at blocking a group of Chinese biopharma firms from tapping into U.S. federal funding has sent shares tumbling in recent days. WuXi Bio, for its part, says it's not affiliated with the military in China.

Biopharma 296
article thumbnail

New Web of Science Grants Index helps researchers develop more targeted grant proposals

Clarivate

Competition for funding is tough and researchers need help to make their grant applications stand out. The Web of Science Grants Index from Clarivate helps researchers seamlessly incorporate valuable awarded grant data from hundreds of funders into their grant proposal development. By exploring what has already been funded, researchers can make informed decisions when applying for new grants.

article thumbnail

Pharma Just Increased the Price of Hundreds of Drugs. PBMs are Minimizing the Impact for Health Plans, Employers and Patients

MedCity News

While pharmaceutical companies continue to raise list prices year-over-year, we work behind the scenes to fight the trend by driving competition, negotiating with drugmakers and incentivizing the use of less expensive medicines that deliver the same clinical value.

article thumbnail

How to Prove Marketing Value: Demonstrate Content ROI and Contribution to Sales

Every marketer knows how important it is to prove their efforts drive sales opportunities, but that’s easier said than done. When problems like sales and marketing misalignment, lack of data, and wasted efforts persist, marketers can’t measure, prove, or increase their impact on revenue at a time when demonstrating marketing value is critical. Using analyst and expert data, this guide to marketing impact and content attribution explains: How B2B buyers use content The most common types of conten

article thumbnail

First human subject receives a Neuralink brain implant

pharmaphorum

Elon Musk’s Neuralink company has said it has implanted its wireless brain implant device into a human being for the first time

112
112
article thumbnail

Who's No. 1? With $25B in sales, Merck's Keytruda looks to be the top-selling drug of 2023

Fierce Pharma

With Merck reporting a whopping $25 billion sales haul for | With Merck reporting a whopping $25 billion sales haul for Keytruda on Thursday, the PD-1 cancer superstar appears to be the world’s top-selling drug in 2023. Keytruda looks set to take over the top spot from Pfizer and BioNTech’s Comirnaty, which ruled the previous two years, scoring sales of $55.9 billion in 2022 and $55.1 billion in 2021.

Sales 290
article thumbnail

Moderna leads the development of mRNA vaccines in infectious diseases

Pharmaceutical Technology

The rapid sequencing of the SARS-CoV-2 and the subsequent development of mRNA vaccines led to the authorisation of the first of these vaccines in late 2020.

Leads 111
article thumbnail

Simplifying the Maternal Care Network

MedCity News

A new era in maternal care is emerging with the advent of maternity care management platforms. Innovative organizations are centralizing the coordination of all patient care aspects, seamlessly integrating with providers’ electronic health records, existing workflows, and health information exchanges.

article thumbnail

How to Stay Competitive in the Evolving State of Martech

Marketing technology is essential for B2B marketers to stay competitive in a rapidly changing digital landscape — and with 53% of marketers experiencing legacy technology issues and limitations, they’re researching innovations to expand and refine their technology stacks. To help practitioners keep up with the rapidly evolving martech landscape, this special report will discuss: How practitioners are integrating technologies and systems to encourage information-sharing between departments and pr

article thumbnail

US bill paints some Chinese biotechs as security threats

pharmaphorum

Legislation filed in the US is seeking to block Chinese biotech companies from federal contracts on the grounds they are a national security concern

111
111
article thumbnail

After 'bad launch' remark by CEO, Pfizer's RSV vaccine gains traction in Q4. How will it fare in latest round of GSK showdown?

Fierce Pharma

After 'bad launch' remark by CEO, Pfizer's RSV vaccine gains traction in Q4. How will it fare in latest round of GSK showdown?

279
279
article thumbnail

Pharmaceutical industry: 2023 in retrospect

European Pharmaceutical Review

N-Nitrosamines By far the biggest issue bedevilling industry during 2023 was the continuing N-nitrosamine contamination saga, which was covered in the third issue of EPR 2023. 1 Some five years after the initial NDMA (N-nitrosodimethylamine) contamination issue 2 initially affecting valsartan drug substance, then other active pharmaceutical ingredients (APIs), eg, sartans, ranitidine, metformin, etc; the toxic short alkyl chain N-nitrosamine issue appears, if not resolved, then well on the way t

article thumbnail

How Are Healthcare AI Developers Responding to WHO’s New Guidance on LLMs?

MedCity News

This month, the World Health Organization released new guidelines on the ethics and governance of LLMs in healthcare. Reactions from the leaders of healthcare AI companies have been mainly positive. However, one leader pointed out that fear or the risks associated with LLMs shouldn’t hinder innovation, and another noted that the guidance may have failed to mention a major topic.

article thumbnail

European Clinical Supply Planning: Balancing Cost, Flexibility and Time